PL1819704T3 - Amidowe pochodne kwasu pirolopirydyno-2-karboksylowego użyteczne jako inhibitory fosforylazy glikogenowej - Google Patents

Amidowe pochodne kwasu pirolopirydyno-2-karboksylowego użyteczne jako inhibitory fosforylazy glikogenowej

Info

Publication number
PL1819704T3
PL1819704T3 PL05815826T PL05815826T PL1819704T3 PL 1819704 T3 PL1819704 T3 PL 1819704T3 PL 05815826 T PL05815826 T PL 05815826T PL 05815826 T PL05815826 T PL 05815826T PL 1819704 T3 PL1819704 T3 PL 1819704T3
Authority
PL
Poland
Prior art keywords
pyrrolopyridine
inhibitor
carboxylic acid
acid amide
glycogen phosphorylase
Prior art date
Application number
PL05815826T
Other languages
English (en)
Polish (pl)
Inventor
Jozsef Repasi
Andras Szabo
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of PL1819704T3 publication Critical patent/PL1819704T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL05815826T 2004-12-02 2005-12-02 Amidowe pochodne kwasu pirolopirydyno-2-karboksylowego użyteczne jako inhibitory fosforylazy glikogenowej PL1819704T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63246304P 2004-12-02 2004-12-02
PCT/GB2005/050234 WO2006059165A1 (en) 2004-12-02 2005-12-02 Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase
EP05815826A EP1819704B1 (en) 2004-12-02 2005-12-02 Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase

Publications (1)

Publication Number Publication Date
PL1819704T3 true PL1819704T3 (pl) 2008-12-31

Family

ID=35735250

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05815826T PL1819704T3 (pl) 2004-12-02 2005-12-02 Amidowe pochodne kwasu pirolopirydyno-2-karboksylowego użyteczne jako inhibitory fosforylazy glikogenowej

Country Status (10)

Country Link
US (1) US8664397B2 (enExample)
EP (1) EP1819704B1 (enExample)
JP (1) JP2008521874A (enExample)
AT (1) ATE400574T1 (enExample)
DE (1) DE602005008099D1 (enExample)
DK (1) DK1819704T3 (enExample)
ES (1) ES2309822T3 (enExample)
PL (1) PL1819704T3 (enExample)
PT (1) PT1819704E (enExample)
WO (1) WO2006059165A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2008057930A2 (en) 2006-11-02 2008-05-15 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with retinoic acid receptor agonists
CN103626825B (zh) * 2013-09-30 2015-10-07 承德医学院 靶向肝脏的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
CN103626826B (zh) * 2013-09-30 2015-10-21 承德医学院 含偶氮键的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
CN103626837B (zh) * 2013-09-30 2016-11-23 承德医学院 含生物可裂解二肽的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
CN103819486B (zh) * 2014-01-27 2016-08-17 承德医学院 标记血清糖原磷酸化酶浓度水平的光亲和标记探针分子、其制备方法及医药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021831D0 (en) 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
US7405210B2 (en) * 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
EP1636224B1 (en) 2003-05-21 2010-07-14 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase

Also Published As

Publication number Publication date
DE602005008099D1 (de) 2008-08-21
DK1819704T3 (da) 2008-10-20
US20080293761A1 (en) 2008-11-27
HK1107984A1 (en) 2008-04-25
ATE400574T1 (de) 2008-07-15
US8664397B2 (en) 2014-03-04
JP2008521874A (ja) 2008-06-26
ES2309822T3 (es) 2008-12-16
EP1819704A1 (en) 2007-08-22
PT1819704E (pt) 2008-10-06
WO2006059165A1 (en) 2006-06-08
EP1819704B1 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
TW200833326A (en) Chemical compounds 572
MX2008012490A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
TW200628463A (en) Heteroaryl compounds
MY150787A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
MX2008010884A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1.
UA96961C2 (uk) Азаадамантанові похідні і способи застосування
WO2006047415A3 (en) FACTOR Xa COMPOUNDS
EP1794120A4 (en) peptidase
MXPA06000936A (es) Derivados de nicotinamida utiles como inhibidores de pde4.
TW200633977A (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
TW200628153A (en) Novel compounds
PT1819704E (pt) Derivado amida de ácido pirrolopiridina-2-carboxílico útil como inibidor de glicogénio fosforilase
GB0407025D0 (en) Novel compounds
TNSN06260A1 (en) Process for the preparation of tryptase inhibitors
PT1745010E (pt) Derivados de ciclo-hexil-1,4-diamina substituídos
WO2006031929A3 (en) Thiazolopyridine kinase inhibitors
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
MX2007007446A (es) Procesos para la produccion de 4-aminoquinazolinas.
TW200719889A (en) Amino acid derivatives
TW200745133A (en) New compounds II